Clinical Trial Update: Effect of Long-term Carvedilol to Prevent Decompensation or Death in Patients With Asymptomatic Child-Pugh A5 to B8 Cirrhosis and Clinically Significant Portal Hypertension: a Multicenter Double-blind Randomized Control Trial [Phase 3]

View source ↗

Summary

Phase 3 multicenter double-blind trial assessing long-term carvedilol to prevent hepatic decompensation or death in asymptomatic Child-Pugh A5 to B8 cirrhosis w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cirrhosis
• Portal Hypertension

Drugs mentioned

• Carvedilol (Coreg) (carvedilol)

Snippet

Sponsor: University Hospital, Tours | Conditions: Asymptomatic Cirrhosis, Clinically Significant Portal Hypertension | Phase 3 | Status: NOT_YET_RECRUITING